We predict that breast cancer cells treated with ATZ alone should have a greater proliferation rate associated with stronger EGF signaling activity, while the co-treatment of ATZ+antagonist and ATZ+Curcumin should produce limited proliferation and diminished EGF signaling activity. The gene discussed is EGF; the disease is breast carcinoma.